Lip Gyh 1
1. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
2. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
3. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
4. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
5. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
6. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
7. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
8. 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
9. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe
10. 2025 ESC Guidelines for the management of myocarditis and pericarditis
11. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
12. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry
13. Global burden of metabolic diseases, 1990–2021
14. Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021
1